<DOC>
	<DOCNO>NCT01676766</DOCNO>
	<brief_summary>The purpose study utilize flavoprotein fluorescence fundus autofluorescence detect progression Stargardt macular dystrophy pediatric population course year hope aid future therapeutic risk-benefit decision assessment outcomes . Stargardt macular dystrophy common juvenile-onset macular dystrophy . Despite determination ABCA4 causative gene , clinician challenge variability clinical phenotype . Given recent initiation clinical trial assess novel treatment ( e.g . gene therapy ) , need identify patient bad prognosis . The investigator observe pediatric patient lose central visual function faster adult counterpart . Thus , present ideal cohort determine utility novel modality detect early change . These include flavoprotein fluorescence , new image technique detect mitochondrial dysfunction develop University Michigan . Fundus autofluorescence ( FAF ) another commonly utilized technique evaluate hereditary eye disease . The investigator develop novel mean quantify FAF signature allow documentation severity well detection progression .</brief_summary>
	<brief_title>Novel Quantification Methods Fluorescence Detect Progression Stargardt Disease</brief_title>
	<detailed_description>This study evaluate whether sophisticated test analytic methodology , include fundus autofluorescence ( FAF ) novel non-invasive method measure retinal flavoprotein fluorescence ( FPF ) may use well predict Stargardt macular dystrophy progression monitor treatment effect conventional modality visual acuity visual field . This method involve use novel statistical method assess heterogeneity fundus autofluorescence image . Participants complete 3 visit University Michigan Kellogg Eye Center . Each visit take approximately 2.5 hour . The initial visit include routine clinical eye examination , measurement best-corrected visual acuity , indirect ophthalmoscopy , microperimetry , frequency-domain optical coherence tomography , Goldmann visual field , fundus flavoprotein fluorescence ( FPF ) imaging , fundus autofluorescence ( FAF ) fundus photography . Patients return evaluation 6 12 month initial visit repeat test imaging .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Between age 5 18 year old Clinical diagnosis Stargardt Disease Molecular confirmation Stargardt Disease ( 2 identify mutation ABCA4 ) Visual acuity well 20/100 Limited central vision , define visual acuity worse 20/100 A diagnosis retinal degenerative disease</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Stargardt Disease</keyword>
	<keyword>Macular degeneration</keyword>
	<keyword>Retinal dystrophy</keyword>
</DOC>